if it was Aza-ven alone then it would be gold standard for treating this population by now. the fact is there's no frontline treatment for newly diagnosed AML in elderly. Hence Dr Maiti came up with this idea to combine the two. if you listen to his presentation he explained that Aza-ven exposes certain parts of the cancer cells and makes it easier for the core NK cells to seek them out and kill.
- Forums
- ASX - By Stock
- Ann: ADVENT-AML Phase 1B clinical trial update
CHM
chimeric therapeutics limited
Add to My Watchlist
0.00%
!
0.4¢

if it was Aza-ven alone then it would be gold standard for...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $8.060M |
Open | High | Low | Value | Volume |
0.5¢ | 0.5¢ | 0.4¢ | $15.69K | 3.919M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
26 | 21936206 | 0.4¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.5¢ | 24685267 | 27 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
26 | 21936206 | 0.004 |
38 | 23301940 | 0.003 |
15 | 12300508 | 0.002 |
10 | 59600000 | 0.001 |
0 | 0 | 0.000 |
Price($) | Vol. | No. |
---|---|---|
0.005 | 22760116 | 26 |
0.006 | 13828910 | 16 |
0.007 | 5660001 | 5 |
0.008 | 8542434 | 6 |
0.009 | 2767672 | 5 |
Last trade - 16.10pm 13/06/2025 (20 minute delay) ? |
Featured News
CHM (ASX) Chart |